Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for IPA within the last 6 months
See all filings within the past 6 months

Company News

Jul 22, 2021 08:02 ET
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced new results from its TATX-03 PolyTope™ Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant.
Read full article
Jul 15, 2021 08:08 ET
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSX VENTURE:IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the Company will host a conference call to discuss its financial results and business highlights for the full fiscal year 2021, on Wednesday, July 28, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Investors interested in submitting questions must do so in advance o
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 202139,71622,262
Jun 30, 202117,454-20,321
Jun 15, 202137,775127
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

ImmunoPrecise Antibodies Ltd. is a technology platform company that supports pharmaceutical and biotechnology companies. The Company discover, develop, engineer and manufacture therapeutic antibodies against all classes of disease targets. The Company transforms the conventional multi-vendor antibody discovery model by providing a suite of services tailored to improve antibody genetic diversity and epitope coverage, to discover antibodies against rare epitopes. The Company offers support to its partners with customized, computational project design, antigen preparation, an on-site vivarium, immunization services, discovery platforms, functional antibody testing, lead candidate selection, antibody optimization, antibody engineering and manufacturing. The Company's services include B cell sorting, phage display, abthena bispecifics, LucinaTech Humanization, affinity maturation, immunization, hybridoma, sequencing and cell line development.

See business summary



Search (past week) for $IPA.CA IPA.V